SUBSCRIBE
SUBSCRIBE
News   Drug Development

Trigen Holdings AG Presents Phase II Results For Its Intravenous Direct Thrombin Inhibitor, TGN 255, For The Prevention Of Clotting During Hemodialysis

July 17, 2006 | 
1 min read
Results presented at the XLIII European Renal Association and European Dialysis and Transplantation Association (ERA-EDTA) Congress in Glasgow, Scotland
Clinical research Phase II Europe
MORE ON THIS TOPIC
IN PARTNERSHIP WITH ECLIPSEBIO
The mRNA Revolution You Haven’t Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines
July 10, 2025
 · 
1 min read
 · 
Lori Ellis
AbbVie's office in South San Francisco, California
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Business consultant. Hands help a businessman is falling from a graph vector
Rare diseases
Ultragenyx, Mereo Plummet After Late-Stage Trial for Rare Genetic Disorder Appears To Fall Short
July 10, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
ALS
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data
July 8, 2025
 · 
3 min read
 · 
Heather McKenzie